Oshadi Drug Administration Report issue

For profit Phase 1 Phase 2
Founded: Rehovot Israel (2010)
Status: No NME R&D (2010)

Organization Overview

First Clinical Trial
2010
NCT01120912
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (5)

cytarabine (cytosar-u) (1 trial)

docetaxel (taxotere) (1 trial)

mitoxantrone (novantrone) (1 trial)

oshadi d (8 trials)

oshadi r (7 trials)

Drugs in Phase 1 Trials (1)

insulin human (humulin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Basal Cell (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 1 (Phase 2)

Leukemia (Phase 2)

Leukemia, Lymphoid (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Mesothelioma (Phase 2)

Neoplasm Metastasis (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 9
  • # of Trial APIs: 6